A new Atrium hire gets options on 11,000 shares and 5,500 restricted units
Atrium Therapeutics (Nasdaq: RNA) granted equity inducement awards to a new non-executive employee on August 20, 2026. The awards include non-qualified options for 11,000 shares at an exercise price of $13.48 and 5,500 restricted stock units, both with multi-year time-based vesting schedules. These grants were approved by the board's independent Human Capital Management Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Atrium Therapeutics (RNA): RA Capital and affiliates report 0% beneficial ownership
RA Capital Management, L.P., and its affiliates, including Peter Kolchinsky and Rajeev Shah, have filed an amended Schedule 13G/A, reporting 0% beneficial ownership of Atrium Therapeutics (RNA) common stock as of June 30, 2026. This indicates they hold no shares and possess no voting or dispositive power over Atrium Therapeutics stock, falling below the 5% ownership threshold. The filing confirms that each reporting person now owns 5 percent or less of the common stock.
Form 8K Atrium Therapeutics Inc For: 13 August By Investing.com
This article reports on the filing of a Form 8K by Atrium Therapeutics Inc. for August 13. The brief notice highlights this corporate action as reported by Investing.com, a financial markets news service. No further details about the content of the Form 8K are provided within the article.
Sessa Capital discloses 8.8% Atrium Therapeutics (RNA) ownership through managed funds
Sessa Capital IM, L.P. and John Petry have reported a beneficial ownership of 1,500,000 shares of Atrium Therapeutics, Inc. common stock, which accounts for 8.8% of the outstanding shares. This disclosure was made via a SCHEDULE 13G SEC filing, indicating a passive investment. The shares are held by Sessa funds managed by Sessa Capital IM, L.P., with Sessa Capital (Master), L.P. having rights to dividends or sale proceeds from over 5% of the common stock.
T. Rowe Price Associates (RNA) discloses 8.6% Atrium Therapeutics ownership in 13G/A
T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 1,472,984 shares in Atrium Therapeutics Inc., which constitutes an 8.6% stake in the company. The filing indicates that T. Rowe Price Associates holds sole voting power over 1,472,772 shares and sole dispositive power over all 1,472,984 shares, with no shared voting or dispositive powers. Despite the disclosure, the firm explicitly denies beneficial ownership of these securities.
Form 8K Atrium Therapeutics Inc For: 13 August By Investing.com
Investing.com reports that Atrium Therapeutics Inc. filed a Form 8K on August 13th. The brief article mentions the filing of this corporate document. No further details about the content of the Form 8K are provided.
Atrium Therapeutics, Inc. (RNA) Stock Price, News, Quote & History
Atrium Therapeutics, Inc. (RNA), formerly Prosensa Holding B.V. Ordinary Shares, is a biopharmaceutical company focused on developing RNA therapeutics for cardiomyopathies. The company's stock is currently trading at $12.84, with a slight increase after hours. Analysts maintain a "Buy" rating with a target price of $25.00, despite the company showing negative earnings per share and a negative profit margin.
Atrium Therapeutics, Inc. Q2 2026: Revenue $3M, EPS $(1.18) — 10-Q Summary
Atrium Therapeutics, Inc. reported its Q2 2026 results, with revenue declining to $3M from $3.85M in the prior year, and a diluted loss per share of $(1.18), worse than $(0.75) year-over-year. Despite the financial decline, the company highlighted an increase in collaboration revenue, clinical progress with FDA clearance for ATR 1072, and the successful spin-off from Avidity. R&D and G&A expenses increased to support planned clinical launches and public-company operations.
Form 8K Atrium Therapeutics Inc For: 13 August By Investing.com
This article from Investing.com is a brief announcement regarding an 8K filing by Atrium Therapeutics Inc. for August 13th. The content is very minimal, essentially serving as a headline to notify readers of the regulatory filing, without providing any further details about the filing itself.
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
Atrium Therapeutics has received a $15 million milestone payment from Bristol Myers Squibb for successfully delivering a lead compound targeting a cardiology indication. This payment is part of their global collaboration to develop RNA-based therapies for cardiovascular diseases, with Atrium eligible for up to $1.35 billion in R&D milestones and $825 million in commercial milestones, plus royalties. The collaboration leverages Atrium's RNA delivery platform, designed to selectively target the underlying causes of genetically driven cardiac diseases.
Atrium Therapeutics (Nasdaq:RNA) - Stock Analysis
This Simply Wall Street analysis provides an overview of Atrium Therapeutics (Nasdaq:RNA), a biopharmaceutical company focused on RNA therapeutics for cardiomyopathies. The report highlights the company's recent FDA clearance for its investigational new drug ATR 1072 for PRKAG2 syndrome, its Q1 2026 earnings exceeding analyst expectations, and identifies key risks such as forecasted declining earnings and current unprofitability. It also details the company's financial health, recent announcements, and market performance.
Atrium Therapeutics, Inc. (RNA) Stock Analysis: Exploring a Potential 102.59% Upside in the Booming RNA Therapeutics Market
Atrium Therapeutics, Inc. (RNA) is a biotechnology company focused on RNA therapeutics for cardiomyopathies, attracting investor attention despite its current stock price near its 52-week low. Analysts project a potential upside of 102.59%, with an average target price of $25.00, supported by a strong buy consensus. The company, which has a market cap of $211.08 million, is in a developmental stage with a high revenue growth of 1,148.30% and strategic collaborations with pharmaceutical giants.
H.C. Wainwright Initiates Atrium Therapeutics(RNA.US) With Buy Rating, Announces Target Price $25
H.C. Wainwright has initiated coverage on Atrium Therapeutics (RNA.US) with a Buy rating. The firm has set a target price of $25 for the company's stock. This new coverage and price target suggest a positive outlook from H.C. Wainwright on Atrium Therapeutics' future performance.
Enterprise value to EBITDA forward of Atrium Therapeutics, Inc. – NASDAQ:RNA
This article from TradingView presents financial data for Atrium Therapeutics, Inc. (NASDAQ:RNA), specifically focusing on its enterprise value to EBITDA forward. It indicates that the market for RNA was closed with no trades at the time of publication. The content appears to be an excerpt from a financial data platform, providing a snapshot of a specific financial metric for the company.
Atrium Therapeutics, Inc. Revenue Breakdown – NASDAQ:RNA
Atrium Therapeutics, Inc. (NASDAQ: RNA) generated $18.60 million USD in revenue last year, primarily from its Ribonucleic Acid Therapeutics segment, which contributed $18.62 million USD. The majority of this revenue, $18.62 million USD, came from the United States. This represents an increase from the previous year's total revenue of $10.90 million USD.
Avidity Biosciences Inc (RNA) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Avidity Biosciences Inc (RNA), detailing its volatility, financial risk, and investment risk. It highlights the company's current risk score of 4.87, ranking 79 out of 155 in the Pharmaceuticals industry, and discusses its beta value of 0.00, indicating a tendency to underperform in up-trending markets but experience smaller declines in down-trending markets. Key metrics such as maximum drawdown, volatility, Sharpe ratio, and liquidity are presented over various timeframes.
Avidity Biosciences Inc (RNA) Financial Health: Profitability & Balance Sheet Analysis
Avidity Biosciences Inc (RNA) has a robust financial score of 9.13, ranking 13th in the Pharmaceuticals industry. The company reported a significant year-over-year revenue increase of 1148.25% to $19.64M and an 85.63% increase in net profit. However, specific data for Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns have not been disclosed by the company.
Avidity Biosciences Inc (RNA) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Avidity Biosciences Inc (RNA), detailing its price momentum score of 3.55 and market performance. It outlines key support and resistance levels, and presents a comprehensive overview of various technical indicators, including MACD, RSI, and moving averages, along with their current signals. The analysis also includes an FAQ section to clarify common concepts like technical ratings and moving averages, concluding with a neutral signal based on current indicators and moving averages.
BlackRock (RNA holder) discloses 6.6% Atrium Therapeutics stake in amended ownership filing
BlackRock, Inc. has filed an amended ownership report (SCHEDULE 13G/A) disclosing a 6.6% beneficial ownership stake in Atrium Therapeutics, Inc. This represents 1,135,757 shares of common stock, with BlackRock holding sole voting power over 1,119,668 shares and sole dispositive power over all beneficially owned shares. The filing indicates that no single client of BlackRock holds more than five percent of Atrium Therapeutics' outstanding common shares.
Avidity Biosciences Inc (RNA) Income Statement
This article provides the quarterly and annual income statement data for Avidity Biosciences Inc (RNA), detailing its financial performance including total revenue, operating expenses, net income, and earnings per share. It covers financial figures from FY2019Q1 up to FY2026Q1, allowing for an in-depth analysis of the company's financial trends over time. The document also includes an FAQ section explaining how to interpret income statements and key financial metrics for RNA stock.
Avidity Biosciences Inc (RNA) Cash Flow
This article provides a detailed historical cash flow statement for Avidity Biosciences Inc (RNA), covering quarterly data for operating, investing, and financing activities. It also includes an overview of key cash flow metrics and changes year-over-year, as well as FAQs explaining what operating, investing, financing, and free cash flows represent. The data presented aims to help evaluate the company's financial soundness and stability.
Stock Score & Comprehensive Stock Analysis of Avidity Biosciences Inc (RNA) - Tradingkey
This article provides a comprehensive stock analysis of Avidity Biosciences Inc (RNA) from TradingKey, highlighting its robust fundamentals, high growth potential, and fair valuation within the Pharmaceuticals industry. The analysis details the company's innovative RNA therapeutics, its strong financial performance, high institutional ownership, and mixed short-to-medium term price predictions from analysts. It also outlines TradingKey's methodology for generating stock scores across various dimensions, including financial health, valuation, earnings forecasts, price momentum, institutional confidence, and risk assessment.
Avidity Biosciences Inc (RNA) Institutional Confidence
Avidity Biosciences Inc (RNA) has an institutional shareholding score of 3.00, placing it 92nd out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 29.04%, marking a significant quarter-over-quarter decrease of 70.62%. Paul Tudor Jones is the largest institutional shareholder, holding 73.39K shares, which represents 0.42% of shares outstanding.
Avidity Biosciences Inc (RNA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Avidity Biosciences Inc (RNA), detailing its financials by region. While segment and detailed regional data are not yet disclosed by the company, the article notes a United States revenue contribution of $18.62 million. It includes current stock performance and market capitalization details.
RNA|Avidity Biosciences Inc|Price:11.635|Chg%:+0.145
Avidity Biosciences Inc is a biopharmaceutical company focused on developing a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The company has three programs in clinical development: Del-desiran for myotonic dystrophy type 1 (DM1), Delpacibart braxlosiran for facioscapulohumeral muscular dystrophy (FSHD), and Del-zota for Duchenne muscular dystrophy (DMD). The article also provides detailed company information, including executive leadership, shareholdings, and institutional investor data.
RNA|Avidity Biosciences Inc|Price:11.489|Chg%:-0.421
Avidity Biosciences Inc. (RNA) is trading at $11.489, down 3.53%. Despite recent stock market underperformance, the company shows strong fundamentals, high growth potential, and is considered fairly valued by analysts. Avidity Biosciences is a biopharmaceutical company developing RNA therapeutics called antibody oligonucleotide conjugates (AOCs) with three programs in clinical development.
Atrium Therapeutics awards stock grants to 8 new hires
Atrium Therapeutics (Nasdaq: RNA) granted equity awards to eight new non-executive employees on June 20, 2026, under its 2026 Employment Inducement Incentive Award Plan. The awards include options for 66,000 shares at $12.66 per share and 33,000 Restricted Stock Units (RSUs), with multi-year time-based vesting schedules. These grants, approved under Nasdaq Listing Rule 5635(c)(4), were made outside existing stockholder-approved equity incentive plans to attract and retain new talent.
Avidity Biosciences (RNA) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary
Avidity Biosciences presented a summary of its achievements and strategic updates at the 7th Annual Evercore ISI HealthCONx Healthcare Conference. The company reported consistent positive data across its three neuromuscular programs, expanded into precision cardiology, and is advancing next-generation technology. With $1.6 billion in cash, Avidity Biosciences is progressing towards registrational trials, with key updates expected for its DM1, FSHD, and DMD programs in 2025.
Avidity Biosciences (RNA) Morgan Stanley 23rd Annual Global Healthcare Conference summary
Avidity Biosciences (RNA) presented updates at the Morgan Stanley 23rd Annual Global Healthcare Conference, highlighting three ongoing late-stage clinical trials with BLA filings for Del-zota (DMD) expected by year-end, followed by Del-zota (myotonic dystrophy) and Del-brax (FSHD) in late 2026. The company discussed key data readouts, an optimized dosing strategy for its AOC platform, and the design of the HARBOR trial for myotonic dystrophy, which has regulatory alignment across major regions.
Avidity Biosciences looks to RNA therapeutics as investors weigh long-term potential
Avidity Biosciences focuses on developing RNA-based therapies for rare genetic diseases, emphasizing a specialized approach that appeals to investors due to recent advancements in biotech and drug development. The company's strategy involves influencing gene expression at the molecular level, creating a scalable platform with potential for multiple applications. Investors closely watch its clinical development, pipeline diversity, regulatory approval pathways, and potential collaborations to assess long-term value against inherent clinical development risks.
Avidity Biosciences Inc (RNA) Financial Health: Profitability & Balance Sheet Analysis
Avidity Biosciences Inc (RNA) shows robust financial health with a score of 9.39, ranking highly within the Pharmaceuticals industry. The company reported significant growth, with its latest quarterly revenue increasing by 1148.25% year-over-year and net profit rising by 85.63%. Its operating efficiency is noted as high, although detailed financial data for various metrics like cash flow and total assets has not yet been disclosed.
Avidity Biosciences Stock - Long-term strategy around RNA therapeutics
This article focuses on Avidity Biosciences' long-term strategy, clinical pipeline, and funding status as a pre-commercial biotechnology company. The company specializes in developing RNA-based therapies for rare muscle and neuromuscular diseases using antibody-oligonucleotide conjugates (AOCs). Key programs target myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy, with a goal to expand into broader disease areas.
Avidity Biosciences Inc (RNA) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Avidity Biosciences Inc (RNA), highlighting its current earnings forecast score of 8.00 and an average price target of $72.00, with an upside of 96.08%. Based on analytics from 2 analysts, the stock receives a "Strong Buy" rating. The report also details expected revenue for the next quarter and past EPS performance.
Avidity Biosciences Inc (RNA) Institutional Confidence
Avidity Biosciences Inc (RNA) has an institutional shareholding score of 3.00, placing it 94th out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 29.04%, marking a significant quarter-over-quarter decrease of 70.62%. Paul Tudor Jones is the largest institutional shareholder, holding 0.42% of outstanding shares with a 0.67% increase in his holdings.
Avidity Biosciences Inc (RNA) Valuation: PE, PB & Fair Value Analysis
Avidity Biosciences Inc (RNA) has a valuation score of 8.73, placing it 70th out of 157 companies in the Pharmaceuticals industry. The company's current P/E ratio is -4.38, showing a significant change from its recent high and low. Relevant data for P/B, P/S, and P/CF ratios are not yet disclosed by the company.
Avidity Biosciences Inc (RNA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Avidity Biosciences Inc (RNA), detailing its business segments, regional revenue, and profit contribution. It shows that the company's revenue from the United States was $18.62 million, with segment and regional data not yet fully disclosed. The article highlights the current stock price and market capitalization, providing a snapshot of the company's financial overview.
Novartis RNA drug acquired in $12B Avidity deal notches a trial win
Novartis announced that del-brax, an RNA drug acquired in its $12 billion deal with Avidity Biosciences, met its primary biomarker endpoint in a Phase 1/2 study for facioscapulohumeral muscular dystrophy (FSHD). The drug, delpacibart braxlosiran, is designed to restore muscle function by targeting the DUX4 gene, which is expressed incorrectly in FSHD patients. This positive trial data partially validates Novartis's acquisition and paves the way for a Phase 3 trial and potential accelerated approval, with investors also anticipating results from two other AOC drugs in development.
Here's Why We're Not Too Worried About Atrium Therapeutics' (NASDAQ:RNA) Cash Burn Situation
Atrium Therapeutics (NASDAQ:RNA) has a cash runway of about 4.1 years based on its current cash burn rate of US$65m and cash reserves of US$268m. While its cash burn increased significantly by 154% in the last year, this was accompanied by a strong revenue growth of 237%, which the article suggests may justify the increased spending. Despite concerns about potential shareholder dilution if the company needs to raise more capital, the overall financial situation is considered relatively comfortable.
Avidity Biosciences Price Target Announced at $25.00/Share by Leerink Partners
Leerink Partners has set a price target of $25.00 per share for Avidity Biosciences (NASDAQ: RNA). This new target suggests a potential for significant movement in the company's stock, according to the analyst firm. Investors will likely be watching how Avidity Biosciences reacts to this updated valuation.
Avidity Biosciences (RNAM) Schedule 13G/A: RA Capital, Kolchinsky, Shah update ownership
Avidity Biosciences (RNAM) has filed a Schedule 13G/A, an amendment by RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky, and Rajeev Shah. This filing updates their beneficial ownership, indicating positions equal to or below 5% of the class as of March 31, 2026. The reporting persons collectively disclaim status as a "group," emphasizing that their disclosures are individual rather than collaborative for control purposes.
Atrium Therapeutics Reports First Quarter 2026 Financial Results
Atrium Therapeutics, Inc. reported its first-quarter 2026 financial results, highlighting its launch as an independent publicly traded company (Nasdaq: RNA) and significant progress in its precision cardiology pipeline. The company earned a $15 million milestone payment from Bristol Myers Squibb and advanced its lead programs, ATR 1072 and ATR 1086, towards clinical trials. Atrium Therapeutics ended the quarter with $267.8 million in cash and cash equivalents, which it believes is sufficient to fund operations through key clinical proof-of-concept milestones.
Facioscapulohumeral Muscular Dystrophy Market: Pharma Pipeline Fuels Rapid Expansion – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics
The Facioscapulohumeral Muscular Dystrophy (FSHD) market is projected for significant growth between 2020 and 2034, driven by increasing prevalence and a robust pharmaceutical pipeline. Key companies like Dyne Therapeutics, Avidity Biosciences, and Fulcrum Therapeutics are developing late-stage therapies, including gene-targeting treatments and Antibody Oligonucleotide Conjugates (AOCs™). The market is seeing considerable advancements in clinical trials, with several candidates showing promise in reducing DUX4 gene expression and improving patient outcomes, with a large unmet need for treatments.
Facioscapulohumeral Muscular Dystrophy Market: Pharma Pipeline Fuels Rapid Expansion - DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics
The Facioscapulohumeral Muscular Dystrophy (FSHD) market is poised for rapid expansion, driven by an increasing prevalence of the disease and a robust pharmaceutical pipeline. Key companies like Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, and Fulcrum Therapeutics are developing therapies such as DYNE-301, MC-DX4, and Losmapimod, with several candidates showing promising clinical results, including Sarepta Therapeutics' siRNA programs and Avidity Biosciences' delpacibart braxlosiran. The market's growth is further supported by governmental efforts to facilitate research and a high likelihood of reimbursement for upcoming therapies, given the current lack of approved treatments for FSHD.
Who is the CEO of Avidity Biosciences in 2026? Sarah Boyce's Bio
Sarah Boyce is the President and CEO of Avidity Biosciences, a role she has held since October 2019. With over 25 years of leadership experience in the pharmaceutical and biopharmaceutical industries, she has been crucial in transforming Avidity from a research-focused company into a clinical-stage firm. Her leadership has guided the company through significant milestones, including funding rounds and an IPO, while advancing multiple RNA therapies into clinical development.
Linklaters advises on USD 11.0 bn financing by Novartis of the acquisition of Avidity Biosciences
Linklaters advised a global underwriting syndicate on an USD 11 billion SEC-registered bond issuance by Novartis. The proceeds will be used for general corporate purposes and to repay a bridge loan that financed Novartis' USD 12 billion acquisition of Avidity Biosciences. The international Linklaters team was led by Marco Carbonare, Kevin Roy, and Danelle Le Cren.
Biotech CAMP4 taps veteran CFO as it pushes SYNGAP1 drug to trial
CAMP4 Therapeutics (Nasdaq: CAMP) has appointed Michael MacLean, a veteran biotech CFO with over 35 years of experience, to its Board of Directors. This strategic move coincides with the company advancing its CMP-002 program for SYNGAP1-related disorder towards a planned first-in-human Phase 1/2 clinical trial. MacLean's extensive background includes leadership roles at Avidity Biosciences, Akcea Therapeutics, PureTech Health, and Biogen, bringing valuable financial and operational expertise to CAMP4 during this critical growth phase.
Novartis Completes $12-Bn Acquisition of Avidity Biosciences
Novartis has finalized its $12 billion acquisition of Avidity Biosciences to enhance its late-stage neuroscience pipeline. Avidity specializes in RNA therapeutics and antibody oligonucleotide conjugates (AOCs) for rare genetic neuromuscular diseases. This acquisition provides Novartis with Avidity’s AOC platform and three key late-stage programs targeting Myotonic Dystrophy Type 1, Facioscapulohumeral Muscular Dystrophy, and Duchenne Muscular Dystrophy.
Novartis acquisition spin-off pioneers RNA therapeutics for the heart
Atrium Therapeutics, a spin-off from Avidity Biosciences following its acquisition by Novartis, is pioneering precision RNA therapeutics for rare, genetic cardiomyopathies. The company, launched with $270 million in funding and a Novartis-validated delivery platform, aims to develop treatments that target the underlying cause of these severe heart conditions. Atrium plans to file INDs for its lead assets in late 2026 and 2027, with the potential to expand its reach beyond rare diseases to broader cardiomyopathy patient populations.
Avidity Biosciences (RNA) Q4 2025 earnings summary
Avidity Biosciences (RNA) reported
[15-12G] Avidity Biosciences, Inc. SEC Filing
This article announces an SEC filing by Avidity Biosciences, Inc. (RNAM) of Form 15, which is a certification and notice of termination of registration under Section 12(g) or suspension of duty to file reports under Sections 13 and 15(d) of the Securities Exchange Act of 1934. The filing was signed by Jaime Huertas, Secretary, on March 9, 2026. The company is headquartered in San Diego, California, and has common stock with a par value of $0.0001 per share.
